GlassScriptPhysician profile
Gina Yu
NPI 1407432057
$2,936.06
in general payments reported to CMS, 2019-2025
8 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.34 · 2022: $95.49 · 2023: $297 · 2024: $98.00 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Travel and Lodging: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.19 |
| Travel and Lodging | $1,266.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,618.26 | 2025 | Travoprost Intraocular Implant - Idose, Radius Xr, Istent Infinite |
| Sight Sciences, INC. | $419.01 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $274.50 | 2023-2025 | Hydrus Microstent, Clareon |
| Abbvie INC. | $238.86 | 2022-2025 | |
| Biogen, INC. | $128.04 | 2023 | |
| Nova Eye, INC. | $118.60 | 2025 | |
| Stryker Corporation | $94.34 | 2021 | |
| Bausch & Lomb Americas INC. | $44.45 | 2023 | Lotemax Sm, Vyzulta, Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.